In preclinical studies, CD40 agonist therapy has elicited tumor regression when used in combination with chemotherapy.59, 60, 61 In the KPC model of pancreatic adenocarcinoma, combination treatment with gemcitabine and an agonist CD40 antibody resulted in regression of spontaneous tumors in 30% of mice.59 Agonist CD40 treatment in combination with gemcitabine and nab‐paclitaxel also resulted in tumor regression of subcutaneously implanted KPC tumor cells and prolonged overall survival compared to anti‐CD40 therapy or chemotherapy alone.59, 61. Here, CD40 is linked to pancreatic adenocarcinoma.